Page 91 - 《中国药房》2024年10期

world study[J]. J Allergy Clin Immunol Pract，2019，7（1）： 315-316.
156-164.e1. [20] 林江涛，邢斌，唐华平，等. 2013—2014年我国城区支气
[12] FLEURENCE R L，HOLLENBEAK C S. Rates and pro- 管哮喘急性发作住院患者的临床特征及住院费用的回
babilities in economic modelling：transformation，transla‐ 顾性调查[J]. 中华结核和呼吸杂志，2017，40（11）：
tion and appropriate application[J]. Pharmacoeconomics， 830-834.
2007，25（1）：3-6. LIN J T，XING B，TANG H P，et al. A multi-center retro‐
[13] 国务院人口普查办公室.2010年全国第六次人口普查报 spective study of clinical characteristics and hospitaliza‐
告[R/OL].（2011-04-28）[2023-10-09]. https：//www.stats. tion costs of patients hospitalized for asthma exacerbation
gov.cn/english/Statisticaldata/CensusData/rkpc2010/indexch. in China during 2013-2014[J]. Chin J Tuberc Respir Dis，
htm. 2017，40（11）：830-834.
Population Census Office under the State Council. Tabula‐ [21] LLOYD A，PRICE D，BROWN R. The impact of asthma
tion on the 2010 population census of the People’s Republic exacerbations on health-related quality of life in moderate
of China 2010[R/OL].（2011-04-28）[2023-10-09]. https：// to severe asthma patients in the UK[J]. Prim Care Respir
www.stats.gov.cn/english/Statisticaldata/CensusData/ J，2007，16（1）：22-27.
rkpc2010/indexch.htm. [22] MCQUEEN R B，SHEEHAN D N，WHITTINGTON M
[14] HUANG G M，LIU J T，LI T，et al. Long-term trends of D，et al. Cost-effectiveness of biological asthma treat‐
asthma mortality in China from 2000 to 2019：a joinpoint ments：a systematic review and recommendations for future
regression and age-period-cohort analysis[J]. Healthcare， economic evaluations[J]. Pharmacoeconomics，2018，36
2022，10（2）：346. （8）：957-971.
[15] LIN J T，XING B，TANG H P，et al. Hospitalization due [23] TUGAY D，TOP M，AYDIN Ö，et al. Real-world patient-
to asthma exacerbation：a China asthma research network level cost-effectiveness analysis of omalizumab in patients
（CARN）retrospective study in 29 provinces across main‐ with severe allergic asthma treated in four major medical
land China [J]. Allergy Asthma Immunol Res，2020，12 centers in Turkey[J]. J Med Econ，2023，26（1）：720-730.
（3）：485-495. [24] ZHOU H，LU Y M，WU B，et al. Cost-effectiveness of
[16] 胡俊华，张艳霞，胡艳秋，等. 不同剂量吸入性皮质类固 omalizumab for the treatment of inadequately controlled
醇联合长效 β2激动剂治疗成人持续性哮喘患者的效果 severe allergic asthma in Chinese children[J]. J Asthma，
及成本-效益分析[J]. 中国药物滥用防治杂志，2022，28 2020，57（1）：87-94.
（6）：736-739，744. [25] CAI D，SHI S，JIANG S，et al. Estimation of the cost-
HU J H，ZHANG Y X，HU Y Q，et al. Immune function effective threshold of a quality-adjusted life year in China
and cost-benefit analysis of different doses of inhaled cor‐ based on the value of statistical life[J]. Eur J Health Econ，
ticosteroids combined with long-acting β2 agonists in the 2022，23（4）：607-615.
treatment of adult persistent asthma[J]. Chin J Drug Abuse [26] OCHALEK J，WANG H Y，GU Y Y，et al. Informing a
Prev Treat，2022，28（6）：736-739，744. cost-effectiveness threshold for health technology assess‐
[17] ZHANG M，JIN M L，ZHOU X，et al. Effectiveness of ment in China：a marginal productivity approach[J]. Phar‐
omalizumab in patients with severe allergic asthma：a macoeconomics，2020，38（12）：1319-1331.
retrospective study in China[J]. Respir Med，2021，186： [27] LI J，KANG J，WANG C Z，et al. Omalizumab improves
106522. quality of life and asthma control in Chinese patients with
[18] ALANGARI A A. Corticosteroids in the treatment of moderate to severe asthma：a randomized phase Ⅲ study
acute asthma[J]. Ann Thorac Med，2014，9（4）：187-192. [J]. Allergy Asthma Immunol Res，2016，8（4）：319-328.
[19] 郭平平，鲁丽杰，崔琦. 急诊救护临床护理路径在哮喘患 [28] LI N，CAO L F，ZHANG M，et al. Response to omali‐
者 中 的 应 用 效 果 [J]. 黑 龙 江 中 医 药 ，2019，48（4）： zumab as an add-on therapy in the treatment of allergic
315-316. asthma in adult Chinese patients：a retrospective study[J].
GUO P P，LU L J，CUI Q. Application effect of clinical Vaccines，2022，10（12）：2068.
nursing pathway of emergency rescue in asthma patients （收稿日期：2023-09-11 修回日期：2024-04-18）
[J]. Heilongjiang J Tradit Chin Med，2019，48（4）： （编辑：孙 冰）

中国药房 2024年第35卷第10期 China Pharmacy 2024 Vol. 35 No. 10 · 1237 ·